VT-CANNATROL
11.7.2024 14:04:28 CEST | Business Wire | Press release
Cannatrol, the creators of the only total dry, cure and store system for the cannabis industry, announced today an exclusive partnership with Paralab Green, Europe’s premier distributor of cannabis processing solutions, establishing distribution of the company’s patented Vaportrol® Technology throughout Europe.
“This partnership truly represents the best of cannabis processing,” said Jane Sandelman, CEO and Co-Founder of Cannatrol. “Paralab Green has established relationships within the European cannabis industry and has a unique understanding of the rapidly growing market. We look forward to opening international access to Cannatrol’s science-backed technology that will benefit cultivators—and ultimately consumers.”
Paralab Green supplies over 70% of licensed production facilities throughout the European Union, offering a range of instrumentation for the cannabis industry, from production to quality control.
“The European market continues to lead the way in Good Manufacturing Practices (GMP) compliance, and this partnership with Cannatrol is a pivotal addition that enhances our portfolio at Paralab Green,” said Rui Soares, CEO of Paralab Green. “The Cannatrol team brings invaluable scientific expertise to optimize and simplify the drying and curing process. This collaboration reinforces our commitment to excellence, raising industry standards and delivering exceptional value to our customers.”
Cannatrol systems ensure consistent water activity and vapor pressure, delivering elevated product quality, increased yields, GMP regulatory compliance and bottom-line improvements. Cannatrol’s patented postharvest technology is proven to increase curing efficiency, and delivers on average 16% higher terpene retention when compared to traditional drying and curing methods, according to independent testing by The Cannabis Research Coalition.
In addition to Europe, Paralab Green operates in Israel, North Africa and Latin America—opening the door for operators in those regions to access Cannatrol technology.
To learn more about Cannatrol’s Vaportrol® Technology, visit cannatrols.com.
About Cannatrol
Cannatrol supports commercial cannabis cultivation by streamlining and tightly controlling the critical drying, curing processes as well as postharvest storage. With patented Vaportrol® Technology, the system controls water loss by regulating the vapor pressure and ensures the correct final water activity, critical for terpene preservation, maximized potency, increased yield and premium quality. Cannatrol’s environmental control solution ensures consistent results for every climate and geography, taking the guesswork and risk out of seasonal humidity and temperature swings. Learn more at cannatrols.com.
About Paralab Green
Paralab Green, a division of Paralab with 32 years of industry leadership, specializes in providing innovative equipment solutions tailored for the cannabis industry. With a background in serving the pharmaceutical, biotechnology, energy, and chemical sectors, Paralab Green brings extensive expertise to cannabis cultivation, extraction, and production. Operating from offices in Portugal and Spain, we are the trusted solution provider for the majority of licensed producers in Europe. Paralab Green combines technical prowess with exceptional customer support to drive innovation and set new standards in the cannabis sector. Learn more at paralab-green.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711844879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom